Galectin-3 Immunoassay Epitope Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing heart failure (HF) lack a reliable and specific assay for galectin-3, a biomarker predictive of HF, due to its similarity to other galectins and propensity to bind various molecules, making it difficult to distinguish and quantify accurately in clinical samples.
Innovation Solution
Development of a sandwich assay using two binding moieties that specifically target non-overlapping epitopes on the N-terminus of galectin-3, allowing for reproducible and sensitive detection of galectin-3 levels in clinical samples, enabling improved diagnosis and prognosis of HF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional assays are used to detect galectin-3, then the assay can be performed, but the measurement precision is poor due to similarity with other galectins and non-specific binding
Solution Approach 1:
The patent divides the galectin-3 protein into specific epitopic regions (N-terminal and C-terminal domains) and uses different binding moieties to target each region. This segmentation allows the assay to specifically recognize galectin-3 distinct from other galectins by focusing on unique epitopic sequences rather than relying on generic galectin detection methods.
Solution Approach 2:
The patent employs binding moieties with specific local recognition capabilities - one targeting the N-terminal epitopic region and another targeting the C-terminal epitopic region. Each binding moiety is optimized for its specific region, creating local quality differentiation that enables high-specificity detection while avoiding cross-reactivity with other galectins.
2Device complexity
If a single binding moiety is used to detect galectin-3, then the assay is simpler, but the measurement precision and reliability are insufficient due to non-overlapping epitope binding requirements
Solution Approach 1:
The patent segments the detection system into multiple binding moieties, each targeting distinct epitopic regions of galectin-3. This segmentation increases measurement precision by reducing cross-reactivity with other galectins, while the modular nature of the components keeps the overall assay structure manageable.
Solution Approach 2:
The patent combines multiple binding moieties in a sandwich assay configuration where one binds to the N-terminus and another binds to the C-terminus. This merging of multiple specific binders creates a synergistic effect that enhances both measurement precision and reliability while maintaining reasonable assay complexity through standardized immunoassay formatting.
3Loss of information
If galectin-3 is detected in clinical samples, then diagnostic information can be obtained, but the reliability is compromised due to the protein's propensity to bind various molecules
Solution Approach 1:
The patent uses binding moieties with highly specific local recognition for galectin-3 epitopes on the N- and C-termini. This local quality specificity ensures that only galectin-3 is detected, not other galectins or molecules that galectin-3 might bind in the complex clinical sample environment, thereby preventing non-specific binding interference from compromising diagnostic accuracy.
Solution Approach 2:
The binding moieties act as intermediaries that selectively bridge the detection system to galectin-3. By using these specific intermediaries that recognize unique epitopic regions, the assay filters out non-specific binding interference and maintains reliable diagnostic information even in the presence of complex sample matrices.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a reliable and specific means to quantify galectin-3 levels, aiding in the diagnosis, prognosis, and management of HF by accurately distinguishing it from other galectins, thereby improving patient triage and treatment outcomes.
Implementation Method 1
two binding moieties that bind specifically to at least two separate, non-overlapping epitopes on the N-terminus of galectin-3
Data Source
AI summary
The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.